Slow virus is a retrovirus that can stably express target genes for a long time after integration into the host cell chromosome. Compared to other retroviruses such as adenovirus, lentiviruses can not only infect dividing cells but also quiescent cells. Therefore, lentiviral vectors have been widely used in preclinical gene research and gene therapy.

However, the use of viral vectors for random insertion of exogenous genes carries potential risks, which may lead to the integration of viral vectors into the host cell's oncogenes or tumor suppressor genes, triggering insertional mutagenesis, thereby activating oncogenes or inhibiting tumor suppressor genes, and increasing cancer risk. These potential side effects have attracted widespread attention, therefore there is an urgent need to develop universal integration site detection methods to assess the safety risks of viral vectors in cell therapy applications. GentleGen Lenti NGSafety TM technology platform provides comprehensive, highly sensitive, and accurate detection of lentiviral vector genome integration sites, dedicated to accelerating cell therapy technology to benefit patients faster and safer.